Evidence map›Paper›PMID 29177885›Full record

Trial reportDrugs & aging2017

Clopidogrel Therapy in Patients with Cardiovascular Disease Undergoing Transurethral Resection of the Prostate: A Step Towards Individualization.

Petros Tzimas, Maria Tsoumani, Dimitrios Giannakis, Kallirroi Kalantzi, Anastasios Petrou, Vasileios Chantzichristos, Nikolaos Sofikitis, Georgios Papadopoulos, Haralampos Milionis, Alexandros Tselepis

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Drugs & aging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 73% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Petros TzimasDepartment of Anesthesiology and Postoperative Intensive Care, Faculty of Medicine, School of Health Sciences, University of Ioannina, University Campus, 45110, Ioannina, Greece. petzimas@gmail.com.ORCID 0000-0002-0327-2859
Maria TsoumaniDepartment of Chemistry, Laboratory of Biochemistry, Atherothrombosis Research Centre, University of Ioannina, Ioannina, Greece.
Dimitrios GiannakisDepartment of Urology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
Kallirroi KalantziDepartment of Chemistry, Laboratory of Biochemistry, Atherothrombosis Research Centre, University of Ioannina, Ioannina, Greece.
Anastasios PetrouDepartment of Anesthesiology and Postoperative Intensive Care, Faculty of Medicine, School of Health Sciences, University of Ioannina, University Campus, 45110, Ioannina, Greece.
Vasileios ChantzichristosDepartment of Chemistry, Laboratory of Biochemistry, Atherothrombosis Research Centre, University of Ioannina, Ioannina, Greece.
Nikolaos SofikitisDepartment of Urology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
Georgios PapadopoulosDepartment of Anesthesiology and Postoperative Intensive Care, Faculty of Medicine, School of Health Sciences, University of Ioannina, University Campus, 45110, Ioannina, Greece.
Haralampos MilionisDepartment of Chemistry, Laboratory of Biochemistry, Atherothrombosis Research Centre, University of Ioannina, Ioannina, Greece.
Alexandros TselepisDepartment of Chemistry, Laboratory of Biochemistry, Atherothrombosis Research Centre, University of Ioannina, Ioannina, Greece.
University of Ioannina · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe objective of this study was to test platelet function pre- and peri-operatively in clopidogrel-treated patients undergoing transurethral resection of the prostate.

methodsThis was a pilot study involving 20 male patients treated with clopidogrel (75 mg/day) for the secondary prevention of cardiovascular disease and scheduled for elective transurethral resection of the prostate. Platelet function testing with light transmittance aggregometry in platelet-rich plasma of four samples (T0, T1, T2, and T3 drawn on the same day, 3 and 7 days of clopidogrel cessation and 24-h post-operatively, respectively) was performed and evaluated in each patient. P-selectin membrane expression was evaluated using monoclonal antibodies.

resultsThe platelet response to adenosine diphosphate 5 µΜ and 20 µΜ at T0 were 42 ± 15 and 60 ± 14%, respectively. After discontinuation of clopidogrel, corresponding maximum aggregation values at T1 were 60 ± 16 and 74 ± 14%, and increased to 69 ± 16 and 79 ± 18% at T2. No significant difference in platelet aggregation values were noted between T1 and T2, while similar aggregation values were recorded at T3.

conclusionsOur findings indicate that in patients undergoing transurethral resection of the prostate, platelet activation is similar 3 and 7 days from clopidogrel cessation. These results may be of relevance in subjects at increased thrombotic risk prior to a surgical procedure carrying a high-bleeding risk.

Indexed as

AgedCardiovascular DiseasesClopidogrelHumansMalePilot ProjectsPlatelet AggregationPlatelet Aggregation InhibitorsPlatelet Function TestsPrecision MedicineProstatic HyperplasiaP-SelectinTiclopidineTransurethral Resection of ProstateClopidogrelPlatelet Aggregation InhibitorsP-SelectinSELP protein, humanTiclopidine

Identifiers

PMID29177885
OpenAlexW2768787219

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.